Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.76 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.76 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18597368 | 0.91 | HDAC3 (0.77) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL443222 | 0.89 | HDAC3 (0.80) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL417537 | 0.89 | HDAC3 (0.60) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL445641 | 0.88 | HDAC6 (0.73) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL446834 | 0.87 | HDAC3 (0.77) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| Abexinostat SCHEMBL444280 | 0.86 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| Abexinostat SCHEMBL29489677 | 0.86 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL14765130 | 0.86 | HDAC3 (0.76) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL445587 | 0.86 | HDAC6 (0.75) | HDAC3HDAC1HDAC2HDAC10HDAC8 | |
| Abexinostat SCHEMBL29544306 | 0.85 | HDAC6 (1.00) | HDAC3HDAC1HDAC2HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8389570-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8026371-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC3 2/4885HDAC1 1/4885HDAC2 10/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC3 2/4885HDAC1 1/4885HDAC2 10/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC3 2/4885HDAC1 1/4885HDAC2 10/4885 |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC3 2/4885HDAC1 1/4885HDAC2 10/4885 |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | HDAC3 2/4885HDAC1 1/4885HDAC2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.